# ProJenX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/projenx

- Industry: Biotechnology
- Headquarters: US
- Website: www.projenx.com/
- Total disclosed funding: $20M
- Latest round: Series A (Nov 2, 2023)
- Investors on record: 1

## About

Founded in 2021 and based in New York, US, ProJenX, Inc. operates as a clinical-stage biotechnology company that researches and develops therapies for ASL and other neurodegenerative diseases with Prosetin, a MAP4K inhibitor therapy. The company was co-founded by Arie Zask, Emily Lowry, Hynek Wichterle, and Brent Stockwell. As of 2023, the company is led by its CEO, Stan Abel. In November 2023, ProJenX, Inc. raised USD 15 million in Series A funding led by Medical Excellence Capital. 

The company is developing novel, brain-penetrant therapies for the treatment of debilitating brain diseases, with an initial focus on ALS. The company's aims to make prosetin, a scientifically validated, first-in-class MAP4 kinase inhibitor, available for ALS and other neurodegenerative diseases.

## Funding rounds

- Series A, Nov 2, 2023, $15M — Medical Excellence Capital
- Seed, Jan 21, 2022, $5.1M — Medical Excellence Capital

## Investors

- Medical Excellence Capital (https://capitalatlas.ai/funds/medical-excellence-capital) — Seed, Series A